CoChat

Gut hormone co-agonists for the treatment of obesity: from bench to bedside

Nogueiras, Ruben, Nauck, Michael A., Tschöp, Matthias H. · 2023 · Nature Metabolism

The DOI matches its Crossref record; 98 of the 99 references it cites were found in a registry or an index.

Abstract

The discovery and development of so-called gut hormone co-agonists as a new class of drugs for the treatment of diabetes and obesity is considered a transformative breakthrough in the field. Combining action profiles of multiple gastrointestinal hormones within a single molecule, these novel therapeutics achieve synergistic metabolic benefits. The first such compound, reported in 2009, was based on balanced co-agonism at glucagon and glucagon-like peptide-1 (GLP-1) receptors. Today, several classes of gut hormone co-agonists are in development and advancing through clinical trials, including dual GLP-1-glucose-dependent insulinotropic polypeptide (GIP) co-agonists (first described in 2013), and triple GIP-GLP-1-glucagon co-agonists (initially designed in 2015). The GLP-1-GIP co-agonist tirzepatide was approved in 2022 by the US Food and Drug Administration for the treatment of type 2 diabetes, providing superior HbA1c reductions compared to basal insulin or selective GLP-1 receptor agonists. Tirzepatide also achieved unprecedented weight loss of up to 22.5%-similar to results achieved with some types of bariatric surgery-in non-diabetic individuals with obesity. In this Perspective, we summarize the discovery, development, mechanisms of action and clinical efficacy of the different types of gut hormone co-agonists, and discuss potential challenges, limitations and future developments.

Overview

Integrity signals

Registry

Crossref · 10.1038/s42255-023-00812-z

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 98 references

Cited by

See all 102

Metadata

Authors
Nogueiras, R., Nauck, M. A., & Tschöp, M. H.
Affiliations
  • St. Josef-Hospital (DE)
  • Helmholtz Munich (DE)
Corresponding author
Tschöp, Matthias H.
Venue
Nature Metabolism
Published
2023-06-12
Volume
5
Issue
6
Pages
933-944
ISSN
2522-5812 (ISSN-L)
OpenAlex
W4380319050
Cited by
102
References
99
Citations by year
2026: 21 · 2025: 33 · 2024: 41 · 2023: 7
FWCI
3.68
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
obesity treatment, type 2 diabetes, tirzepatide, GLP-1 receptor agonists, GIP receptor agonist, glucagon receptor agonist, glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, weight loss, drug development, mechanism of action
MeSH terms
Diabetes Mellitus, Type 2, Gastrointestinal Hormones, Glucagon, Humans, Obesity, United States, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gut hormone co-agonists for the treatment of obesity: from bench to bedside. https://app.cochat.ai/papers/10.1038/s42255-023-00812-z
The paper
Nogueiras, R., Nauck, M. A., & Tschöp, M. H. (2023). Gut hormone co-agonists for the treatment of obesity: from bench to bedside. Nature Metabolism. https://doi.org/10.1038/s42255-023-00812-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.